{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-047880","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.893556+00:00","generated_at":"2026-06-10T01:46:08.227916+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Stockholders approve stock issuance on conversion of Series A Preferred for Pionyr acquisition","bullets":["Special meeting on October 11, 2023; 37,464,898 shares outstanding.","Proposal 1 (stock issuance on conversion of Series A Preferred) approved: 25,681,604 for, 12,086 against, 1,156 abstain.","1,647,531 shares excluded from Nasdaq vote but counted under Delaware law.","Proposal 2 (adjournment if needed) approved: 26,947,409 for, 394,239 against, 729 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-047880","json":"https://secwatch.observer/filing/0001140361-23-047880.json","markdown":"https://secwatch.observer/filing/0001140361-23-047880.md","text":"https://secwatch.observer/filing/0001140361-23-047880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000114036123047880/0001140361-23-047880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000114036123047880/ef20012370_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:46:08.227916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a640bb678e341d765d40fe97774ebaac77e54aa9","claim":"ImageneBio, Inc. shareholders approved Issuance of common stock upon conversion of Series A Non-Voting Convertible Preferred Stock in connection with the acquisition of Pionyr Immunotherapeutics, Inc. at the 2023-10-11 meeting.","evidence_excerpt":"The Company’s stockholders approved, in accordance with Nasdaq Listing Rule 5635(a), the issuance of the Company’s common stock, par value $0.001 per share (“Common Stock”), upon conversion of the Company’s Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (“Proposal No. 1\"), issued in connection with the acquisition of Pionyr Immunotherapeutics, Inc. (the “Acquisition”). The votes cast at the Special Meeting were as follows: For Against Abstain 25,681,604 12,086 1,156","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000114036123047880/0001140361-23-047880-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}